{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T04:02:13Z","timestamp":1791000133052,"version":"4.1.0"},"reference-count":39,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000774","name":"DTRA","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000774","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plospathogens.org"],"crossmark-restriction":false},"short-container-title":["PLoS Pathog"],"abstract":"<jats:p>Smallpox was the most rampant infectious disease killer of the 20<jats:sup>th<\/jats:sup> century, yet much remains unknown about the pathogenesis of the variola virus. Using archived tissue from a study conducted at the Centers for Disease Control and Prevention we characterized pathology in 18 cynomolgus macaques intravenously infected with the Harper strain of variola virus. Six macaques were placebo-treated controls, six were tecovirimat-treated beginning at 2 days post-infection, and six were tecovirimat-treated beginning at 4 days post-infection. All macaques were treated daily until day 17. Archived tissues were interrogated using immunohistochemistry, <jats:italic>in situ<\/jats:italic> hybridization, immunofluorescence, and electron microscopy. Gross lesions in three placebo-treated animals that succumbed to infection primarily consisted of cutaneous vesicles, pustules, or crusts with lymphadenopathy. The only gross lesions noted at the conclusion of the study in the three surviving placebo-treated and the Day 4 treated animals consisted of resolving cutaneous pox lesions. No gross lesions attributable to poxviral infection were present in the Day 2 treated macaques. Histologic lesions in three placebo-treated macaques that succumbed to infection consisted of proliferative and necrotizing dermatitis with intracytoplasmic inclusion bodies and lymphoid depletion. The only notable histologic lesion in the Day 4 treated macaques was resolving dermatitis; no notable lesions were seen in the Day 2 treated macaques. Variola virus was detected in all three placebo-treated animals that succumbed to infection prior to the study\u2019s conclusion by all utilized methods (IHC, ISH, IFA, EM). None of the three placebo-treated animals that survived to the end of the study nor the animals in the two tecovirimat treatment groups showed evidence of variola virus by these methods. Our findings further characterize variola lesions in the macaque model and describe new molecular methods for variola detection.<\/jats:p>","DOI":"10.1371\/journal.ppat.1012007","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T18:22:27Z","timestamp":1708626147000},"page":"e1012007","update-policy":"https:\/\/doi.org\/10.1371\/journal.ppat.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Smallpox lesion characterization in placebo-treated and tecovirimat-treated macaques using traditional and novel methods"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-6420-3367","authenticated-orcid":true,"given":"Todd M.","family":"Bell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Facemire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy J.","family":"Bearss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo Lynne","family":"Raymond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiankun","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Shamblin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice A.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas W.","family":"Grosenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis E.","family":"Hruby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inger K.","family":"Damon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur J.","family":"Goff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric M.","family":"Mucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,2,22]]},"reference":[{"issue":"3","key":"ppat.1012007.ref001","first-page":"397","article-title":"Smallpox: emergence, global spread, and eradication","volume":"15","author":"F. Fenner","year":"1993","journal-title":"Hist Philos Life Sci"},{"issue":"5","key":"ppat.1012007.ref002","first-page":"422","article-title":"Smallpox eradication.","volume":"95","author":"DA Henderson","year":"1980","journal-title":"Public Health Rep"},{"issue":"4","key":"ppat.1012007.ref003","first-page":"535","article-title":"Principles and lessons from the smallpox eradication programme","volume":"65","author":"DA Henderson","year":"1987","journal-title":"Bull World Health Organ"},{"issue":"11\u201312","key":"ppat.1012007.ref004","doi-asserted-by":"crossref","first-page":"638","DOI":"10.5694\/j.1326-5377.1999.tb123833.x","article-title":"nurture and my experience with smallpox eradication","volume":"171","author":"Fenner F. Nature","year":"1999","journal-title":"Med J Aust"},{"issue":"8","key":"ppat.1012007.ref005","doi-asserted-by":"crossref","first-page":"e222","DOI":"10.1016\/S1473-3099(21)00382-0","article-title":"Biodefence research two decades on: worth the investment?","volume":"21","author":"CM Long","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"ppat.1012007.ref006","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1089\/bsp.2013.0047","article-title":"Federal agency biodefense funding, FY2013-FY2014.","volume":"11","author":"TK Sell","year":"2013","journal-title":"Biosecur Bioterror"},{"issue":"2","key":"ppat.1012007.ref007","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1089\/153871303766275763","article-title":"Anthrax 2001: observations on the medical and public health response.","volume":"1","author":"E Gursky","year":"2003","journal-title":"Biosecur Bioterror."},{"issue":"S2","key":"ppat.1012007.ref008","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.2105\/AJPH.2017.303963","article-title":"Public Health Preparedness Funding: Key Programs and Trends From 2001 to 2017.","volume":"107","author":"CR Watson","year":"2017","journal-title":"Am J Public Health."},{"issue":"8","key":"ppat.1012007.ref009","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJM199808203390811","article-title":"Poxvirus dilemmas\u2014monkeypox, smallpox, and biologic terrorism","volume":"339","author":"JG Breman","year":"1998","journal-title":"N Engl J Med"},{"issue":"5","key":"ppat.1012007.ref010","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1001\/jama.1997.03550050090039","article-title":"Biological terrorism. Preparing to meet the threat","volume":"278","author":"JD Simon","year":"1997","journal-title":"JAMA"},{"issue":"1","key":"ppat.1012007.ref011","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.antiviral.2007.10.001","article-title":"FDA perspective on antivirals against biothreats: communicate early and often","volume":"78","author":"R Roberts","year":"2008","journal-title":"Antiviral Res"},{"issue":"2","key":"ppat.1012007.ref012","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3201\/eid0802.010164","article-title":"Public health assessment of potential biological terrorism agents","volume":"8","author":"LD Rotz","year":"2002","journal-title":"Emerg Infect Dis"},{"key":"ppat.1012007.ref013","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.antiviral.2019.06.005","article-title":"The development and approval of tecoviromat (TPOXX((R))), the first antiviral against smallpox.","volume":"168","author":"M Merchlinsky","year":"2019","journal-title":"Antiviral Res"},{"issue":"1","key":"ppat.1012007.ref014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2007.07.003","article-title":"Discovery and development of antiviral drugs for biodefense: experience of a small biotechnology company","volume":"77","author":"TC Bolken","year":"2008","journal-title":"Antiviral Res"},{"issue":"5","key":"ppat.1012007.ref015","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1177\/0300985810372506","article-title":"Establishing efficacy of human products using animals: the US food and drug administration\u2019s \"animal rule\".","volume":"47","author":"PJ Snoy","year":"2010","journal-title":"Vet Pathol"},{"issue":"105","key":"ppat.1012007.ref016","first-page":"37988","article-title":"New drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible.","volume":"67","author":"Food, Drug Administration HHS","year":"2002","journal-title":"Final rule. Fed Regist"},{"issue":"6979","key":"ppat.1012007.ref017","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/nature02331","article-title":"Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox","volume":"428","author":"PL Earl","year":"2004","journal-title":"Nature"},{"issue":"12","key":"ppat.1012007.ref018","doi-asserted-by":"crossref","first-page":"e0122622","DOI":"10.1128\/aac.01226-22","article-title":"New Perspectives on Antimicrobial Agents: Tecovirimat for Treatment of Human Monkeypox Virus","volume":"66","author":"CE DeLaurentis","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"673","key":"ppat.1012007.ref019","doi-asserted-by":"crossref","first-page":"eade7646","DOI":"10.1126\/scitranslmed.ade7646","article-title":"In vitro and in vivo efficacy of tecovirimat against a recently emerged 2022 monkeypox virus isolate.","volume":"14","author":"BM Warner","year":"2022","journal-title":"Sci Transl Med."},{"issue":"4","key":"ppat.1012007.ref020","doi-asserted-by":"crossref","first-page":"e61514","DOI":"10.1371\/journal.pone.0061514","article-title":"Pharmacokinetics and interspecies allometric scaling of ST-246, an oral antiviral therapeutic for treatment of orthopoxvirus infection.","volume":"8","author":"A Amantana","year":"2013","journal-title":"PLoS One."},{"issue":"7","key":"ppat.1012007.ref021","doi-asserted-by":"crossref","first-page":"4296","DOI":"10.1128\/AAC.00208-15","article-title":"Treatment with the smallpox antiviral tecovirimat (ST-246) alone or in combination with ACAM2000 vaccination is effective as a postsymptomatic therapy for monkeypox virus infection.","volume":"59","author":"A Berhanu","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"ppat.1012007.ref022","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/jac\/dku545","article-title":"ST-246 is a key antiviral to inhibit the viral F13L phospholipase, one of the essential proteins for orthopoxvirus wrapping","volume":"70","author":"S Duraffour","year":"2015","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"ppat.1012007.ref023","doi-asserted-by":"crossref","first-page":"6246","DOI":"10.1128\/AAC.00977-13","article-title":"Efficacy of tecovirimat (ST-246) in nonhuman primates infected with variola virus (Smallpox).","volume":"57","author":"EM Mucker","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"ppat.1012007.ref024","doi-asserted-by":"crossref","first-page":"5564","DOI":"10.1128\/JVI.03426-12","article-title":"Effects of postchallenge administration of ST-246 on dissemination of IHD-J-Luc vaccinia virus in normal mice and in immune-deficient mice reconstituted with T cells","volume":"87","author":"M Zaitseva","year":"2013","journal-title":"J Virol"},{"issue":"3","key":"ppat.1012007.ref025","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1128\/AAC.00959-12","article-title":"Pharmacokinetic and pharmacodynamic modeling to determine the dose of ST-246 to protect against smallpox in humans","volume":"57","author":"JM Leeds","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"ppat.1012007.ref026","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2217\/fvl.11.27","article-title":"Development of the small-molecule antiviral ST-246 as a smallpox therapeutic.","volume":"6","author":"DW Grosenbach","year":"2011","journal-title":"Future Virol."},{"issue":"5","key":"ppat.1012007.ref027","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01896-18","article-title":"Immune-Mediated Systemic Vasculitis as the Proposed Cause of Sudden-Onset Sensorineural Hearing Loss following Lassa Virus Exposure in Cynomolgus Macaques.","volume":"9","author":"KA Cashman","year":"2018","journal-title":"mBio."},{"issue":"14","key":"ppat.1012007.ref028","article-title":"Nipah virus persists in the brains of nonhuman primate survivors.","volume":"4","author":"J Liu","year":"2019","journal-title":"JCI Insight."},{"issue":"12","key":"ppat.1012007.ref029","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1038\/s41564-022-01259-w","article-title":"Retrospective detection of monkeypox virus in the testes of nonhuman primate survivors.","volume":"7","author":"J Liu","year":"2022","journal-title":"Nat Microbiol"},{"issue":"631","key":"ppat.1012007.ref030","doi-asserted-by":"crossref","first-page":"eabi5229","DOI":"10.1126\/scitranslmed.abi5229","article-title":"Ebola virus persistence and disease recrudescence in the brains of antibody-treated nonhuman primate survivors.","volume":"14","author":"J Liu","year":"2022","journal-title":"Sci Transl Med."},{"key":"ppat.1012007.ref031","doi-asserted-by":"crossref","first-page":"17113","DOI":"10.1038\/nmicrobiol.2017.113","article-title":"Identification and pathological characterization of persistent asymptomatic Ebola virus infection in rhesus monkeys.","volume":"2","author":"X Zeng","year":"2017","journal-title":"Nat Microbiol."},{"issue":"9","key":"ppat.1012007.ref032","doi-asserted-by":"crossref","first-page":"e1008050","DOI":"10.1371\/journal.ppat.1008050","article-title":"Persistent Crimean-Congo hemorrhagic fever virus infection in the testes and within granulomas of non-human primates with latent tuberculosis","volume":"15","author":"DR Smith","year":"2019","journal-title":"PLoS Pathog"},{"issue":"10","key":"ppat.1012007.ref033","doi-asserted-by":"crossref","first-page":"e24832","DOI":"10.1371\/journal.pone.0024832","article-title":"Progression of pathogenic events in cynomolgus macaques infected with variola virus.","volume":"6","author":"V Wahl-Jensen","year":"2011","journal-title":"PLoS One."},{"key":"ppat.1012007.ref034","first-page":"1","article-title":"Emergence of monkeypox: a worldwide public health crisis.","author":"JPS Begum","year":"2023","journal-title":"Hum Cell"},{"issue":"1","key":"ppat.1012007.ref035","doi-asserted-by":"crossref","first-page":"e27931","DOI":"10.1002\/jmv.27931","article-title":"Epidemiological trends and clinical features of the ongoing monkeypox epidemic: A preliminary pooled data analysis and literature review","volume":"95","author":"NL Bragazzi","year":"2023","journal-title":"J Med Virol"},{"issue":"15","key":"ppat.1012007.ref036","first-page":"5624","article-title":"Human monkeypox outbreak: global prevalence and biological, epidemiological and clinical characteristics\u2014observational analysis between 1970\u20132022.","volume":"26","author":"SA Meo","year":"2022","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"1","key":"ppat.1012007.ref037","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa1705688","article-title":"Oral Tecovirimat for the Treatment of Smallpox","volume":"379","author":"DW Grosenbach","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"ppat.1012007.ref038","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1128\/AAC.01596-08","article-title":"ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification","volume":"53","author":"R Jordan","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"ppat.1012007.ref039","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s12985-017-0880-8","article-title":"Validation of a pan-orthopox real-time PCR assay for the detection and quantification of viral genomes from nonhuman primate blood","volume":"14","author":"EM Mucker","year":"2017","journal-title":"Virol J"}],"container-title":["PLOS Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1012007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T18:22:48Z","timestamp":1708626168000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1012007"}},"subtitle":[],"editor":[{"given":"Antonio","family":"Alcam\u00ed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,2,22]]},"references-count":39,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.ppat.1012007","relation":{},"ISSN":["1553-7374"],"issn-type":[{"value":"1553-7374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,22]]}}}